Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Share-based Compensation (2022 - 2025)

Historic Share-based Compensation for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to $3.3 million.

  • Taysha Gene Therapies' Share-based Compensation fell 214.48% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.0 million, marking a year-over-year increase of 953.18%. This contributed to the annual value of $13.1 million for FY2024, which is 6575.59% up from last year.
  • As of Q3 2025, Taysha Gene Therapies' Share-based Compensation stood at $3.3 million, which was down 214.48% from $3.2 million recorded in Q2 2025.
  • Taysha Gene Therapies' Share-based Compensation's 5-year high stood at $5.3 million during Q1 2022, with a 5-year trough of $1.7 million in Q1 2023.
  • Moreover, its 4-year median value for Share-based Compensation was $3.3 million (2025), whereas its average is $3.3 million.
  • Per our database at Business Quant, Taysha Gene Therapies' Share-based Compensation tumbled by 6856.82% in 2023 and then soared by 9092.54% in 2024.
  • Taysha Gene Therapies' Share-based Compensation (Quarter) stood at $4.1 million in 2022, then crashed by 52.04% to $2.0 million in 2023, then surged by 63.41% to $3.2 million in 2024, then grew by 2.15% to $3.3 million in 2025.
  • Its Share-based Compensation stands at $3.3 million for Q3 2025, versus $3.2 million for Q2 2025 and $3.3 million for Q1 2025.